Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing ...

CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.

A patient participating in the Phase III MAGNITUDE trial of nex-z experienced asymptomatic grade 4 liver transaminase elevations, the firm reported.

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

Intellia Therapeutics shares fell 25% amid safety concerns in Phase 3 trials. Check out if today's selloff in NTLA stock is a ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

The company is set to present durability data from the NTLA-2002 Phase 1/2 study for HAE at the European Academy of Allergy and Clinical Immunology (EAACI) conference on June 15, 2025. Additional data ...